About Sudarshan Pharma Industries Limited
Data last updated: 14 July 2026
Sudarshan Pharma Industries Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in scientific services, a part of the broader professional services sector. Incorporated on 23 July 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN L51496MH2008PLC184997. Listed.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹24.97 Cr. Formerly known as Sudarshan Pharma Industries Private Limited and Sudarshan Speciality Chemsolve Private Limited. It is led by directors including Hemal Vasantrai Mehta and Sachin Vasantrai Mehta.
Last AGM: 25 July 2025. Financial statements filed for year ended 31 March 2025. Office: 301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹703.06 Cr, a growth of 39.21% compared to the previous year. The net worth stands at ₹156.32 Cr. Total assets are valued at ₹641.75 Cr (up 59.48% YoY).
The company has a workforce of approximately 9 employees as per the latest available data. Its group structure includes 3 subsidiaries.
The company is associated with 2 brands - Farm2energy, Sudarshan Pharma. As per MCA filings, the company has open charges of ₹288.69 Cr and satisfied charges of ₹71.35 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudarshanpharma.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered Address301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092
-
IndustryProfessional Services, Scientific, Technical, Personal
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has undergone 2 name changes throughout its history. The company was previously known as Sudarshan Pharma Industries Private Limited, and Sudarshan Speciality Chemsolve Private Limited. The current legal name is Sudarshan Pharma Industries Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Sudarshan Pharma Industries Limited | Current |
| Sudarshan Pharma Industries Private Limited | Previous |
| Sudarshan Speciality Chemsolve Private Limited | Previous |
CIN History of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L51496MH2008PLC184997, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51496MH2008PLC184997 | Current |
| U51496MH2008PTC184997 | Previous |
| U51496MH2008PLC184997 | Previous |
Associated Brands with Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited operates two associated brands: Farm2energy and Sudarshan Pharma. These brands represent Sudarshan Pharma Industries Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers online slot gaming with jackpots and integrated e-commerce features for users. | farm2energy.com | |
| Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals. | sudarshanpharma.com |
Competitors & Alternatives of Sudarshan Pharma Industries Limited
Brands and companies operating in the same space as Sudarshan Pharma Industries Limited include Carbo Culture, Vgrid Energy Systems, Kapsera and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Carbo Culture
|
Producer and supplier of biochar | Woodside, United States, United States | 2016 |
Vgrid Energy Systems
|
Compact biomass energy units are generated from farm waste. | Camarillo, United States, United States | 2013 |
Kapsera
|
Biodegradable microfluidic encapsulation technology is developed for agricultural inputs. | Paris, France, France | 2018 |
Takachar
|
Portable biomass upcycling equipment is developed for rural residue processing. | Cambridge, United States, United States | 2018 |
Fibsol
|
Eco-friendly products for agriculture and healthcare are provided using nanofibers. | Chennai, India, India | 2013 |
Plant Impact
|
Biostimulant products are developed to enhance crop yield and quality. | Harpenden, United Kingdom, United Kingdom | 2006 |
Cool Planet
|
Biomass is converted into green fuels and biocarbon products. | Camarillo, United States, United States | 2009 |
Zero Gravity Solutions
|
Nutrient solutions and plant varieties are developed and offered. | Boca Raton, United States, United States | 1983 |
Business Activity of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is engaged in principal business activities including trade and professional, scientific and technical, with detailed activities including wholesale trading, other professional, scientific and technical activities. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | Locked |
Business activity turnover details for Sudarshan Pharma Industries Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is audited by NGST & Associates (ICAI peer reviewed, certificate valid till 2027-08-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| NGST & Associates (ICAI peer reviewed, certificate valid till 2027-08-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is currently managed by 7 directors, with 18 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Sudarshan Pharma Industries Limited FY 2026 filings available
Sudarshan Pharma Industries Limited reported revenue of ₹703.06 Cr (up 39.21% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹703.06 Cr | ₹505.05 Cr | ₹463.54 Cr | ₹461.33 Cr |
| Other Income | ₹8.71 Cr | ₹2.52 Cr | ₹2.61 Cr | ₹1.12 Cr |
| Total Income | ₹711.77 Cr | ₹507.57 Cr | - | - |
| Cost of Materials Consumed | ₹39.06 Cr | ₹8.93 Cr | ₹6.31 Cr | ₹32.27 Lakh |
| Purchases of Stock-in-Trade | ₹652.13 Cr | ₹485.18 Cr | ₹424.04 Cr | ₹457.25 Cr |
| Changes in Inventories | -₹71.81 Cr | -₹54.35 Cr | -₹7.87 Cr | -₹26.62 Cr |
| Employee Benefit Expense | ₹7.44 Cr | ₹4.89 Cr | ₹3.64 Cr | ₹2.98 Cr |
| Finance Costs | ₹25.7 Cr | ₹15.77 Cr | ₹8.94 Cr | ₹5.4 Cr |
| Depreciation & Amortisation | ₹3.79 Cr | - | - | - |
| Other Expenses | ₹24.93 Cr | ₹20.48 Cr | ₹14.61 Cr | ₹12.72 Cr |
| Total Expenses | ₹681.23 Cr | ₹483.12 Cr | ₹450.92 Cr | ₹452.95 Cr |
| Profit Before Exceptional Items & Tax | ₹30.54 Cr | - | - | - |
| Exceptional Items | ₹0 | - | - | - |
| Profit Before Tax | ₹30.54 Cr | ₹21.63 Cr | ₹15.23 Cr | ₹9.5 Cr |
| Total Tax Expense | ₹7.17 Cr | ₹5.75 Cr | ₹3.77 Cr | ₹2.46 Cr |
| Net Profit | ₹23.37 Cr | ₹15.88 Cr | ₹11.46 Cr | ₹7.04 Cr |
| attributable to Owners | ₹23.3 Cr | - | - | - |
| attributable to NCI | ₹6.84 Lakh | - | - | - |
| Other Comprehensive Income | ₹5.05 Lakh | - | - | - |
| Total Comprehensive Income | ₹23.42 Cr | - | - | - |
| EBITDA (computed) | ₹60.03 Cr | - | - | - |
| Basic EPS | ₹0.97 | - | - | - |
| Diluted EPS | ₹0.97 | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹641.75 Cr | ₹402.41 Cr | ₹283.13 Cr | ₹232.48 Cr |
| Non-current Assets | ₹151.48 Cr | ₹67.56 Cr | ₹41.55 Cr | ₹33.86 Cr |
| Current Assets | ₹490.26 Cr | ₹334.85 Cr | ₹241.57 Cr | ₹198.62 Cr |
| Property, Plant & Equipment | ₹77.41 Cr | ₹20.05 Cr | - | - |
| Inventories | ₹218.74 Cr | ₹140.48 Cr | ₹85.74 Cr | ₹74.57 Cr |
| Trade Receivables | ₹233.34 Cr | - | - | - |
| Cash & Equivalents | ₹1.13 Cr | ₹6.28 Lakh | ₹14.35 Lakh | ₹11.72 Cr |
| Equity (Net Worth) | ₹156.32 Cr | - | - | - |
| Equity Share Capital | ₹24.07 Cr | - | - | - |
| Borrowings (Non-current) | ₹28.37 Cr | - | - | - |
| Borrowings (Current) | ₹255.11 Cr | - | - | - |
| Total Debt (computed) | ₹283.47 Cr | - | - | - |
| Current Liabilities | ₹456.12 Cr | ₹259.74 Cr | ₹160.82 Cr | ₹118.48 Cr |
| Total Liabilities | ₹485.43 Cr | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹2.3 Cr | -₹26.09 Cr | -₹73.26 Cr | -₹24.46 Cr |
| Investing Cash Flow | -₹77.7 Cr | -₹20.41 Cr | ₹5.24 Cr | -₹26.33 Cr |
| Financing Cash Flow | ₹80.58 Cr | ₹46.87 Cr | ₹56.44 Cr | ₹62.27 Cr |
| Capital Expenditure | ₹69.1 Cr | ₹58.57 Lakh | - | - |
| Free Cash Flow (computed) | -₹71.4 Cr | -₹26.68 Cr | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹72.2 Lakh | ₹0 |
| Net Change in Cash | ₹58.43 Lakh | ₹36.86 Lakh | -₹11.57 Cr | ₹11.48 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹220.92 Cr | ₹168.01 Cr | ₹168.87 Cr | ₹145.26 Cr |
| Other Income | ₹4.13 Cr | ₹1.52 Cr | ₹1.86 Cr | ₹1.21 Cr |
| Total Income | ₹225.05 Cr | ₹169.52 Cr | ₹170.73 Cr | ₹146.47 Cr |
| Cost of Materials Consumed | ₹20.12 Cr | ₹13.21 Cr | ₹30.95 Lakh | ₹5.42 Cr |
| Purchases of Stock-in-Trade | ₹192.61 Cr | ₹148.81 Cr | ₹171.18 Cr | ₹139.53 Cr |
| Changes in Inventories | -₹22.68 Cr | -₹14.22 Cr | -₹19.17 Cr | -₹15.73 Cr |
| Employee Benefit Expense | ₹2.1 Cr | ₹1.97 Cr | ₹1.78 Cr | ₹1.58 Cr |
| Finance Costs | ₹7.53 Cr | ₹6.28 Cr | ₹5.94 Cr | ₹5.96 Cr |
| Depreciation & Amortisation | ₹1.09 Cr | ₹91.1 Lakh | ₹90.12 Lakh | ₹88.35 Lakh |
| Other Expenses | ₹8.57 Cr | ₹7.36 Cr | ₹5.57 Cr | ₹3.42 Cr |
| Total Expenses | ₹209.34 Cr | ₹164.33 Cr | ₹166.5 Cr | ₹141.06 Cr |
| Profit Before Exceptional Items & Tax | ₹15.7 Cr | ₹5.2 Cr | ₹4.23 Cr | ₹5.41 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹15.7 Cr | ₹5.2 Cr | ₹4.23 Cr | ₹5.41 Cr |
| Total Tax Expense | ₹4.31 Cr | ₹1.05 Cr | ₹35.55 Lakh | ₹1.45 Cr |
| Net Profit | ₹11.39 Cr | ₹4.15 Cr | ₹3.87 Cr | ₹3.96 Cr |
| attributable to Owners | ₹10.73 Cr | ₹4.36 Cr | ₹4.18 Cr | ₹4.03 Cr |
| attributable to NCI | ₹66.62 Lakh | -₹20.87 Lakh | -₹31.09 Lakh | -₹7.82 Lakh |
| Other Comprehensive Income | ₹7.37 Lakh | -₹89,000 | -₹89,000 | -₹89,000 |
| Total Comprehensive Income | ₹11.47 Cr | ₹4.14 Cr | ₹3.86 Cr | ₹3.95 Cr |
| EBITDA (computed) | ₹24.32 Cr | ₹12.39 Cr | ₹11.07 Cr | ₹12.25 Cr |
| Basic EPS | ₹0.48 | ₹0.18 | ₹0.16 | ₹0.16 |
| Diluted EPS | ₹0.47 | ₹0.18 | ₹0.16 | ₹0.16 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹667.5 Cr | ₹502.51 Cr | ₹465.56 Cr | ₹461.33 Cr |
| Other Income | ₹8.4 Cr | ₹2.88 Cr | ₹2.75 Cr | ₹1.12 Cr |
| Total Income | ₹675.9 Cr | ₹505.38 Cr | - | - |
| Cost of Materials Consumed | ₹2.98 Cr | ₹4 Cr | ₹4.82 Cr | ₹32.27 Lakh |
| Purchases of Stock-in-Trade | ₹655.99 Cr | ₹488.59 Cr | ₹427.58 Cr | ₹457.25 Cr |
| Changes in Inventories | -₹70.63 Cr | -₹53.3 Cr | -₹7.87 Cr | -₹26.62 Cr |
| Employee Benefit Expense | ₹6.19 Cr | ₹4.56 Cr | ₹3.5 Cr | ₹2.98 Cr |
| Finance Costs | ₹25.3 Cr | ₹15.96 Cr | ₹9.03 Cr | ₹5.4 Cr |
| Depreciation & Amortisation | ₹3.41 Cr | - | - | - |
| Other Expenses | ₹24.01 Cr | ₹20.15 Cr | ₹14.93 Cr | ₹12.72 Cr |
| Total Expenses | ₹647.23 Cr | ₹481.28 Cr | ₹453.22 Cr | ₹452.95 Cr |
| Profit Before Exceptional Items & Tax | ₹28.67 Cr | - | - | - |
| Exceptional Items | ₹0 | - | - | - |
| Profit Before Tax | ₹28.67 Cr | ₹21.29 Cr | ₹15.1 Cr | ₹9.5 Cr |
| Total Tax Expense | ₹6.69 Cr | ₹5.41 Cr | ₹3.74 Cr | ₹2.46 Cr |
| Net Profit | ₹21.98 Cr | ₹15.88 Cr | ₹11.36 Cr | ₹7.04 Cr |
| Other Comprehensive Income | ₹1.53 Lakh | - | - | - |
| Total Comprehensive Income | ₹22 Cr | - | - | - |
| EBITDA (computed) | ₹57.37 Cr | - | - | - |
| Basic EPS | ₹0.91 | - | - | - |
| Diluted EPS | ₹0.90 | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹594.18 Cr | ₹400.4 Cr | ₹284.84 Cr | ₹232.47 Cr |
| Non-current Assets | ₹149.43 Cr | ₹66.57 Cr | ₹39.64 Cr | ₹33.96 Cr |
| Current Assets | ₹444.75 Cr | ₹333.83 Cr | ₹245.2 Cr | ₹198.51 Cr |
| Property, Plant & Equipment | ₹72.77 Cr | ₹19.46 Cr | - | - |
| Inventories | ₹206.66 Cr | ₹137.04 Cr | ₹84.37 Cr | ₹74.57 Cr |
| Trade Receivables | ₹199.23 Cr | - | - | - |
| Cash & Equivalents | ₹10.9 Lakh | ₹6.28 Lakh | ₹13.12 Lakh | ₹11.71 Cr |
| Equity (Net Worth) | ₹152.71 Cr | - | - | - |
| Equity Share Capital | ₹24.07 Cr | - | - | - |
| Borrowings (Non-current) | ₹30.39 Cr | - | - | - |
| Borrowings (Current) | ₹250.7 Cr | - | - | - |
| Total Debt (computed) | ₹281.09 Cr | - | - | - |
| Current Liabilities | ₹410.05 Cr | ₹257.98 Cr | ₹162.61 Cr | ₹118.46 Cr |
| Total Liabilities | ₹441.47 Cr | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹2.75 Cr | -₹27.85 Cr | -₹73.38 Cr | -₹24.45 Cr |
| Investing Cash Flow | -₹79.71 Cr | -₹20.24 Cr | -₹1.25 Cr | -₹26.33 Cr |
| Financing Cash Flow | ₹82.18 Cr | ₹48.35 Cr | ₹63.05 Cr | ₹62.27 Cr |
| Capital Expenditure | ₹49.99 Cr | ₹53.19 Lakh | - | - |
| Free Cash Flow (computed) | -₹52.74 Cr | -₹28.39 Cr | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹72.2 Lakh | ₹0 |
| Net Change in Cash | -₹27.96 Lakh | ₹25.74 Lakh | -₹11.58 Cr | ₹11.48 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹199.81 Cr | ₹158.37 Cr | ₹167.01 Cr | ₹142.31 Cr |
| Other Income | ₹3.21 Cr | ₹1.69 Cr | ₹2.09 Cr | ₹1.41 Cr |
| Total Income | ₹203.02 Cr | ₹160.06 Cr | ₹169.1 Cr | ₹143.73 Cr |
| Cost of Materials Consumed | ₹1.06 Cr | ₹58.15 Lakh | ₹65.93 Lakh | ₹67.94 Lakh |
| Purchases of Stock-in-Trade | ₹193.57 Cr | ₹151.78 Cr | ₹171.76 Cr | ₹138.89 Cr |
| Changes in Inventories | -₹23.29 Cr | -₹13.65 Cr | -₹21.57 Cr | -₹12.12 Cr |
| Employee Benefit Expense | ₹1.85 Cr | ₹1.68 Cr | ₹1.4 Cr | ₹1.26 Cr |
| Finance Costs | ₹7.27 Cr | ₹6.24 Cr | ₹6.07 Cr | ₹5.71 Cr |
| Depreciation & Amortisation | ₹1 Cr | ₹80.63 Lakh | ₹80.68 Lakh | ₹78.98 Lakh |
| Other Expenses | ₹8.32 Cr | ₹7.21 Cr | ₹5.15 Cr | ₹3.33 Cr |
| Total Expenses | ₹189.78 Cr | ₹154.65 Cr | ₹164.27 Cr | ₹138.53 Cr |
| Profit Before Exceptional Items & Tax | ₹13.23 Cr | ₹5.42 Cr | ₹4.83 Cr | ₹5.19 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹13.23 Cr | ₹5.42 Cr | ₹4.83 Cr | ₹5.19 Cr |
| Total Tax Expense | ₹3.69 Cr | ₹1.11 Cr | ₹42.47 Lakh | ₹1.46 Cr |
| Net Profit | ₹9.54 Cr | ₹4.31 Cr | ₹4.4 Cr | ₹3.73 Cr |
| Other Comprehensive Income | ₹4.14 Lakh | -₹87,000 | -₹87,000 | -₹87,000 |
| Total Comprehensive Income | ₹9.58 Cr | ₹4.3 Cr | ₹4.39 Cr | ₹3.72 Cr |
| EBITDA (computed) | ₹21.51 Cr | ₹12.46 Cr | ₹11.7 Cr | ₹11.7 Cr |
| Basic EPS | ₹0.40 | ₹0.18 | ₹0.18 | ₹0.15 |
| Diluted EPS | ₹0.39 | ₹0.18 | ₹0.18 | ₹0.15 |
Shareholding Pattern of Sudarshan Pharma Industries Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 57.39%, foreign institutional investors hold 19.95%, retail and other public shareholders hold 22.61% of Sudarshan Pharma Industries Limited. The company had 1,346 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% |
| Public | 42.61% | 42.61% | 42.61% | 42.61% | 42.61% | 42.61% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 52.47% |
| Public | 42.61% | 42.61% | 42.61% | 47.53% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +4.92 | - |
Group Structure of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Sudarshan Pharma Industries Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Life Science Chemical Private Limited | U21001GJ2023PTC144108 | - |
| Sudarshan Pharma Lifescience Private Limited | U24299MH2021PTC357350 | - |
| Ratna Lifesciences Private Limited | U74999PN2017PTC168995 | - |
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Sudarshan Pharma Industries Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2026 | Karnataka Bank Ltd. | ₹33.3 Cr | Open |
| 20 Feb 2026 | Bank of India | ₹25 Cr | Open |
| 28 Nov 2025 | Yes Bank Limited | ₹6.98 Cr | Open |
| 05 May 2025 | Indian Bank | ₹30 Cr | Open |
| 26 Dec 2024 | Others | ₹48 Cr | Open |
Total charge records: 25 View all charges
Employees and EPFO Compliance at Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has a workforce of 9 employees as of Mar 27, 2025.
Employee and EPFO history for Sudarshan Pharma Industries Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Sudarshan Pharma Industries Limited
GST registrations and filing compliance for Sudarshan Pharma Industries Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Sudarshan Pharma Industries Limited
Credit ratings, litigation, and regulatory alerts for Sudarshan Pharma Industries Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sudarshan Pharma Industries Limited
MSME payment history for Sudarshan Pharma Industries Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sudarshan Pharma Industries Limited
Corporate group structure for Sudarshan Pharma Industries Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sudarshan Pharma Industries Limited
MCA filings and documents for Sudarshan Pharma Industries Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Sudarshan Pharma Industries Limited
Recent News on Sudarshan Pharma Industries Limited
Frequently Asked Questions about Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is an active public limited company in the professional services sector based in Mumbai, Maharashtra, India. It was incorporated on 23 July 2008 (18+ years old) and is registered under CIN L51496MH2008PLC184997. The company has 9 employees.
Sudarshan Pharma Industries Limited reported revenue of ₹703.06 Cr for FY 2026 (up 39.21% YoY) based on consolidated BSE filings.
The current directors of Sudarshan Pharma Industries Limited are:
- Hemal Vasantrai Mehta - Managing Director
- Sachin Vasantrai Mehta - Managing Director
- Jaya Ankur Singhania - Director
- Vijay Ojha - Additional Director
- Anil Balkrishna Ghogare - Director
- Rushabh Prashant Patil - Director
- Vinay Kumar Pandey - Director
The primary industry of Sudarshan Pharma Industries Limited is professional services. The company specifically operates in scientific. The company is currently active in this sector.
Yes, Sudarshan Pharma Industries Limited is a listed company.
Sudarshan Pharma Industries Limited can be reached at the registered office: 301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali West, Mumbai, Maharashtra, India – 400092, or through the website sudarshanpharma.com.